GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatme…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.23 | $-0.31 | $-0.22 |
| Estimado | $-0.30 | $-0.30 | $-0.26 | $-0.27 |
| Sorpresa | — | +23.3% | -19.2% | +18.5% |
| Métrica | GHRS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -17.3% | -39.2% | +21.9% |
| ROA | -16.7% | -30.9% | +14.2% |
| Current Ratio | 34.13 | 2.73 | +31.40 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -16.7% | — |
| ✗Flujo de caja operativo positivo | −$44M | −$42M |
| ✓Rentabilidad sobre activos al alza | -16.7% | -20.7% |
| ✓Caja operativa/activos supera al ROA | -15.1% | ROA -16.7% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 34.13 | 17.23 |
| ✗Sin aumentar el nº de acciones | 61M | 52M |
| –Margen bruto al alza | — | — |
| –Rotación de activos al alza | — | — |
| Calidad del negocio | FY25 |
|---|---|
| ✗ROCE > 10 % | -21.7% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
GH Research PLC cotiza a 18.15 USD y tiene una capitalización bursátil de $1.2B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud